Peter Heerma Travere Therapeutics, Inc. (TVTX) insider trading activity

Peter Heerma is CHIEF COMMERCIAL OFFICER of Travere Therapeutics, Inc.. Currently has a direct ownership of 113,013 shares of TVTX, which is worth approximately $3.9 Million. The most recent transaction as insider was on Dec 24, 2025, when has been sold 4,980 shares (Common Stock) at a price of $40.0 per share, resulting in proceeds of $199,200. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 113K

11.24% 3M change

4.68% 12M change

Total Value Held $3.9 Million

Peter Heerma Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 24 2025	SELL Open market or private sale	$199,200 $40.0 p/Share	4,980 Reduced 4.22%	113,013 Common Stock
Nov 03 2025	SELL Bona fide gift	-	1,078 Reduced 0.91%	117,993 Common Stock
Oct 31 2025	SELL Open market or private sale	$195,685 $35.0 p/Share	5,591 Reduced 4.48%	119,071 Common Stock
Oct 28 2025	SELL Open market or private sale	$79,860 $30.0 p/Share	2,662 Reduced 2.09%	124,662 Common Stock
Sep 23 2025	SELL Bona fide gift	-	891 Reduced 0.69%	127,324 Common Stock
May 05 2025	SELL Open market or private sale	$37,279 $21.05 p/Share	1,771 Reduced 1.36%	128,215 Common Stock
May 02 2025	BUY Exercise of conversion of derivative security	-	4,920 Added 3.65%	129,986 Common Stock

Feb 12 2025	SELL Open market or private sale	$60,425 $23.53 p/Share	2,568 Reduced 2.01%	125,066 Common Stock
Feb 11 2025	SELL Open market or private sale	$76,850 $25.0 p/Share	3,074 Reduced 2.35%	127,634 Common Stock
Feb 10 2025	BUY Exercise of conversion of derivative security	-	8,000 Added 5.77%	130,708 Common Stock
Feb 03 2025	SELL Open market or private sale	$103,939 $20.12 p/Share	5,166 Reduced 4.04%	122,708 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	21,500 Added 14.39%	127,874 Common Stock
Jan 22 2025	SELL Open market or private sale	$30,000 $18.94 p/Share	1,584 Reduced 1.47%	106,374 Common Stock
Sep 09 2024	SELL Open market or private sale	$25,240 $11.52 p/Share	2,191 Reduced 1.99%	107,958 Common Stock
Sep 05 2024	BUY Grant, award, or other acquisition	-	6,750 Added 5.77%	110,149 Common Stock
Feb 01 2024	SELL Open market or private sale	$35,783 $8.53 p/Share	4,195 Reduced 4.05%	99,503 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	25,000 Added 19.43%	103,698 Common Stock
Jan 23 2024	SELL Open market or private sale	$14,140 $9.07 p/Share	1,559 Reduced 1.94%	78,698 Common Stock
Oct 03 2023	SELL Open market or private sale	$25,500 $8.25 p/Share	3,091 Reduced 3.71%	80,257 Common Stock
Feb 01 2023	SELL Open market or private sale	$38,693 $21.75 p/Share	1,779 Reduced 2.12%	82,069 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	20,250 Added 19.45%	83,848 Common Stock
Jan 24 2023	SELL Open market or private sale	$33,945 $21.9 p/Share	1,550 Reduced 2.38%	63,598 Common Stock
Jan 31 2022	SELL Open market or private sale	$30,825 $27.4 p/Share	1,125 Reduced 1.64%	67,297 Common Stock
Jan 31 2022	BUY Grant, award, or other acquisition	-	9,840 Added 12.57%	68,422 Common Stock
Jan 24 2022	SELL Open market or private sale	$46,837 $24.98 p/Share	1,875 Reduced 3.1%	58,582 Common Stock

Peter Heerma

CHIEF COMMERCIAL OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Value

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Travere Therapeutics, Inc.

Track Activities on TVTX

Account